Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ALX Oncology
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 09, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 04, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 06, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
May 29, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 07, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
April 30, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 24, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
April 09, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
March 05, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces November Investor Conference Participation
November 01, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 10, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Pricing of Public Offering
October 05, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Proposed Public Offering
October 04, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
October 03, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
October 02, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Realigns Executive Leadership Team
September 06, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces September Investor Conference Participation
August 31, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
August 10, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
June 26, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 11, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
May 09, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
April 25, 2023
From
ALX Oncology
Via
GlobeNewswire
Tickers
ALXO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit